
By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
LATEST POSTS
- 1
The largest sun of 2026 rises today as Earth draws closest to our parent star - 2
Newly Built Sichuan Hydropower Bridge Collapses Into River Months After Opening - 3
Is Trump going to war with Venezuela? - 4
Shredded cheese recall: Multiple brands sold at Aldi, Target and Walmart affected over potential metal fragment contamination - 5
Vote in favor of the bloom plan that adds a bit of excellence to your life!
The Development of Shipping: Controlling Towards a More Associated Future
What's your biological age? Experts explain the benefits and risks of at-home tests
Find the Advantages of Positive Nurturing: Supporting Cheerful and Sound Kids
Popular Japanese Hotel Chain Now Lets You Show Up With Just Your Passport
Alleged Huione Group Money Laundering Boss Extradited to China
The Conclusive Manual for Spending plan Travel: Opening Undertakings on a Tight budget
Impact of NIH funding reductions felt in cancer and infectious disease trials
One third of Spanish pork export certificates blocked since swine fever outbreak, minister says
25 of the world’s best sandwiches











